Whilst these results were promising, growing clinical evidence indicates high expression of TUBB3 as a clinical biomarker of taxane resistance in various tumour types (reviewed in [32]), but has been shown to predict sensitivity to epothilone B compounds [58, 59]. Here, TUBB3 is linked to neoplasm.